Mayinglong: Subsidiary Obtains Drug Registration Certificate for Bromfenac Sodium Eye Drops
Ma Ying Long's subsidiary has received a drug registration certificate for Bromfenac Sodium Eye Drops from China's National Medical Products Administration. This medication is intended for the symptomatic treatment of inflammatory conditions affecting the outer and anterior parts of the eye, such as conjunctivitis and scleritis. In separate news, Korea Post is increasing its investment in high-yield assets like AI data centers and European real estate to offset losses in its traditional postal business. AI